TMEM106B and depressive symptom measurement: Drug target MR identified causal associations of genetically predicted TMEM106B level on depression (OR = 0.92, 95% CI = 0.90−0.94, p=2.04 ×10−12) and stroke (OR = 0.90, 95% CI = 0.86−0.95, p=3.53 ×10−5).